SEARCH

SEARCH BY CITATION

References

  • Abildgaard, U. (1992) Tissue factor pathway inhibitor and heparin. Advances in Experimental Medicine and Biology, 313, 199204.
  • Abildgaard, U. (1993) Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis, 23, 103106.
  • Andrew, M. (1995) Developmental haemostasis: relevance to thromboembolic complications in pediatric patients. Thrombosis and Haemostasis, 74, 415425.
  • Andrew, M., Ofosu, F., Schmidt, B., Brooker, L., Hirsh, J. & Buchanan, M. (1988a) Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thrombosis Research, 52, 517527.
  • Andrew, M., Mitchell, L., Berry, L., Schmidt, B. & Hatton, M. (1988b) Fibrinogen has a rapid turnover in the healthy newborn lamb. Pediatric Research, 23, 249252.
  • Andrew, M., O’Brodovich, H. & Mitchell, L. (1988c) Fetal lamb coagulation system during normal birth. American Journal of Hematology, 28, 116118.
  • Andrew, M., Vegh, P., Johnston, M., Bowker, J., Ofosu, F. & Mitchell, L. (1992) Maturation of the hemostatic system during childhood. Blood, 80, 19882005.
  • Andrew, M., Monagle, P. & Brooker, L. (2000) Thromboembolic Complications During Infancy and Childhood. BC. Decker, Hamilton.
  • Brodin, E., Svensson, B., Paulssen, R., Nordoy, A. & Hansen, J. (2004) Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment. Journal of Laboratory and Clinical Medicine, 144, 246253.
  • Broze, Jr, G., Warren, L., Novotny, W., Higuchi, D., Girard, J. & Miletich, J. (1988) The lipoprotein-associated coagulation inhibitor that inhibits factor Xa: insight into its possible mechanism of action. Blood, 71, 335343.
  • Chan, A., Berry, L., Monagle, P. & Andrew, M. (2002) Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thrombosis and Haemostasis, 87, 606613.
  • Chan, A., Berry, L., Paredes, N. & Parmar, N. (2003) Isoform composition of antithrombin in a covalent antithrombin-heparin complex. Biochemical and Biophysical Research Communications, 309, 986991.
  • Francis, J. & Armstrong, D. (1982) Sialic acid and enzymatic desialation of cord blood fibrinogen. Haemostasis, 11, 223228.
  • Hamulyak, K., Nieuwenhuizen, W., Devilee, P. & Hemker, H. (1983) Reevaluation of some properties of fibrinogen, purified from cord blood of normal newborns. Thrombosis Research, 32, 301310.
  • Huang, Z., Wun, T.-C. & Broze (Jnr), G. (1993) Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. The Journal of Biological Chemistry, 268, 2695026955.
  • Hull, R., Raskob, G., Rosenbloom, D., Panju, A., Brill-Edwards, P. & Ginsberg, J. (1990) Heparin for 5 days as compared to 10 days in the initial treatment of proximal venous thrombosis. New England Journal of Medicine, 322, 12601264.
  • Ignjatovic, V., Furmedge, J., Newall, F., Chan, A., Berry, L., Fong, C., Cheng, K. & Monagle, P. (2006a) Age-related differences in heparin response. Thrombosis Research, 118, 741745.
  • Ignjatovic, V., Summerhayes, R., Than, J., Gan, A. & Monagle, P. (2006b) Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. Journal of Thrombosis and Haemostasis, 4, 22802282.
  • Ignjatovic, V., Summerhayes, R., Gan, A., Than, J., Chan, A., Cochrane, A., Bennet, M., Shann, F., Lane, G., Ross-Smith, M. & Monagle, P. (2007) Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? Thrombosis Research, 120, 347351.
  • Kuhle, S., Eulmesekian, P., Kavanagh, B., Massicotte, P., Vegh, P. & Mitchell, L. (2007) A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study. Haematologica, 92, 244247.
  • Lindahl, A. (1994) Tissue factor pathway inhibitor: a potent inhibitor of in-vitro coagulation and in-vivo thrombus formation. Current Opinion in Lipidology, 5, 434439.
  • Lindahl, A., Abildgaard, U., Larsen, L., Staalesen, R., Gangnaes-Hammer, A., Sandset, P., Nordfang, O. & Beck, T. (1991a) Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thrombosis Research, 62, 607614.
  • Lindahl, A., Abildgaard, U. & Staalesen, R. (1991b) The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thrombosis Research, 64, 155168.
  • Lindahl, A., Sandset, P. & Abildgaard, U. (1992) The present status of tissue factor pathway inhibitor. Blood, Coagulation and Fibrinolysis, 3, 439449.
  • McDonald, M., Jacobson, L., Hay, W.J. & Hathaway, W. (1981) Heparin clearance in the newborn. Pediatric Research, 15, 10151018.
  • Monagle, P., Barnes, C., Ignjatovic, V., Furmedge, J., Newall, F., Chan, A., DeRosa, L., Hamilton, S., Ragg, P., Robinson, S., Auldist, A., Crock, C. & Rowlands, S. (2006) Developmental haemostasis: impact for clinical haemostasis laboratories. Thrombosis and Haemostasis, 95, 362372.
  • Monagle, P., Chalmers, E., Chan, A., DeVeber, G., Kirkham, F., Massicotte, P. & Michelson, A. (2008) Antithrombotic therapy in neonates and children: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest, 133, 887S968S.
  • Newall, F., Barnes, C., Ignjatovic, V. & Monagle, P. (2003) Heparin-induced thrombocytopaenia in children. Journal of Paediatrics and Child Health, 39, 289292.
  • Newall, F., Johnston, L., Ignjatovic, V., Summerhayes, R. & Monagle, P. (2009) Refinement and feasibility testing of a manual micro-method for protamine titration. International Journal of Laboratory Hematology, 31, 457461.
  • Newall, F., Ignjatovic, V., Johnston, L. & Monagle, P. (2009a) Unfractionated heparin therapy in infants and children. Pediatrics, 123, e510e518.
  • Newall, F., Ignjatovic, V., Summerhayes, R., Gan, A., Butt, W., Johnston, L. & Monagle, P. (2009b) In vivo age dependency of unfractionated heparin in infants and children. Thrombosis Research, 123, 710714.
  • Newall, F., Ignjatovic, V., Johnston, L., Summerhayes, R., Lane, G., Cranswick, N. & Monagle, P. (2010) Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Thrombosis and Haemostasis, 103, 10851090.
  • Niessen, R., Lamping, R., Peters, M., Lamers, W. & Sturk, A. (1996) Fetal and neonatal development of antithrombin III plasma activity and liver messenger RNA levels in sheep. Pediatric Research, 39, 685691.
  • Nordoy, A. (1963) Difference in the heparin-neutralizing effect of protamine and polybrene as tested by thrombotest. The Scandinavian Journal of Clinical and Laboratory Investigation, 15, 205210.
  • Ostergaard, P., Nordfang, O., Petersen, L., Valentin, S. & Kristensen, H. (1993) Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Haemostasis, 23, 107111.
  • Refn, I. & Vestergaard, L. (1954) The titration of heparin with protamine. Scandinavian Journal of Clinical and Laboratory Investigation, 6, 284287.
  • Sandset, P. (1996) Tissue factor pathway inhibitor (TFPI) – an update. Haemostasis, 26, 154165.
  • Sandset, P. & Abildgaard, U. (1991) Extrinsic pathway inhibitor – the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis, 21, 219239.
  • Sandset, P., Abildgaard, U. & Larsen, M. (1988) Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thrombosis Research, 50, 803813.
  • Sandset, P., Larsen, L., Abildgaard, U., Lindahl, A. & Odegaard, O. (1991) Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood, Coagulation and Fibrinolysis, 2, 425433.
  • Sandset, P., Bendz, B. & Hansen, J. (2000) Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis, 30, 4856.
  • Schmidt, B., Ofosu, F., Mitchell, L., Brooker, L. & Andrew, M. (1989) Anticoagulant effects of heparin in neonatal plasma. Pediatric Research, 25, 405408.
  • Witt, I. & Muller, H. (1970) Phosphorus and hexose content of human foetal fibrinogen. Biochimica et Biophysica Acta, 221, 402404.
  • Witt, I., Muller, H. & Kunzer, W. (1969) Evidence for the existence of foetal fibrinogen. Thrombosis et Diathesis Haemorrhagica, 22, 101109.